How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Veterinary Active Pharmaceutical Ingredients (API) Market
- By Animal Type: Companion Animals, Food-Producing Animals, Aquatic Animals, Equine
- By API Type: Antibiotics, Antiparasitics, Anti-inflammatories, Hormones and Steroids, Vaccines
- By Route of Administration: Oral, Injectable, Topical, Inhalation
- By Therapeutic Application: Infectious Diseases, Parasitic Infections, Inflammatory Conditions, Reproductive Health, Nutritional Supplements
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Companion Animals leads By Animal Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.166 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.174 →
Full report · locked preview
Everything inside the Veterinary Active Pharmaceutical Ingredients (API) Market report
A complete, evidence-based study - 11 chapters and 116 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Animal Type 4
API Type 5
Route of Administration 4
Therapeutic Application 5
Companies profiled
BASF SE
Evonik Industries AG
Zoetis Inc.
Elanco Animal Health Incorporated
Boehringer Ingelheim GmbH
Virbac SA
Merial (now part of Boehringer Ingelheim)
Phibro Animal Health Corporation
Huvepharma AD
Vetoquinol SA
Dechra Pharmaceuticals PLC
Ceva Santé Animale
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →BASF SE
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Evonik Industries AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Zoetis Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Elanco Animal Health Incorporated
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Boehringer Ingelheim GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Virbac SA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Merial (now part of Boehringer Ingelheim)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Phibro Animal Health Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Huvepharma AD
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Vetoquinol SA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Dechra Pharmaceuticals PLC
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Ceva Santé Animale
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Norbrook Laboratories Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Jubilant Life Sciences Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Huvepharma
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,504M by 2033 · 4.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Companion Animals55.5
- Food-Producing Animals9.9
- Aquatic Animals14.6
- Equine20.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$342.9M → $454.0M · 3.6%
Europe$239.0M → $355.2M · 5.1%
Asia Pacific$218.2M → $301.1M · 4.1%
Latin America$135.1M → $206.6M · 5.5%
Middle East and Africa$103.9M → $141.8M · 4.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.702026
4.712027
4.712028
4.722029
4.732030
4.752031
4.752032
4.772033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- BASF SE12.7
- Evonik Industries AG16.3
- Zoetis Inc.13.7
- Elanco Animal Health Incorporated13.8
- Boehringer Ingelheim GmbH5.4
- Virbac SA10.2
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Animal Type16.3%
API Type28.5%
Route of Administration25.7%
Therapeutic Application29.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.1
- Europe24.4
- Asia Pacific20.6
- Latin America14.2
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| BASF SE | 87 | 88 | 84 | 87 | 85 | 84 | 86 |
| Evonik Industries AG | 69 | 88 | 91 | 79 | 85 | 93 | 84 |
| Zoetis Inc. | 72 | 78 | 79 | 72 | 70 | 84 | 76 |
| Elanco Animal Health Incorporated | 59 | 79 | 70 | 64 | 63 | 77 | 69 |
| Boehringer Ingelheim GmbH | 65 | 71 | 64 | 73 | 72 | 73 | 70 |
| Virbac SA | 56 | 57 | 66 | 65 | 51 | 52 | 58 |
| Merial (now part of Boehringer Ingelheim) | 47 | 41 | 59 | 58 | 54 | 41 | 50 |
| Phibro Animal Health Corporation | 49 | 56 | 53 | 41 | 42 | 52 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- BASF SE
- Evonik Industries AG
- Zoetis Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| BASF SE | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Evonik Industries AG | ◐ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Zoetis Inc. | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Elanco Animal Health Incorporated | ◐ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Boehringer Ingelheim GmbH | ◐ | ✓ | − | ◐ | ◐ | − |
| Virbac SA | ◐ | ◐ | − | ✓ | − | ◐ |
| Merial (now part of Boehringer Ingelheim) | − | − | ◐ | ◐ | ◐ | − |
| Phibro Animal Health Corporation | − | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1BASF SE86
2Evonik Industries AG84
3Zoetis Inc.76
4Boehringer Ingelheim GmbH70
5Elanco Animal Health Incorporated69
6Virbac SA58
7Merial (now part of Boehringer Ingelheim)50
8Phibro Animal Health Corporation49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
BASF SEEvonik Industries AG
Challenger3
Strong scale, closing on the leaders.
Zoetis Inc.Elanco Animal Health IncorporatedBoehringer Ingelheim GmbH
Contender1
Focused players with pockets of strength.
Virbac SA
Niche2
Specialists in a single segment or region.
Merial (now part of Boehringer Ingelheim)Phibro Animal Health Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Animal Type in North America, then scale across Veterinary Active Pharmaceutical Ingredients (API) Market — a $112M beachhead inside a $2.14B market.
Beachhead (SOM)$112Mobtainable near-term
Serviceable (SAM)$740Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Companion Animals
Best fit — highest urgency & budget in Animal Type.
Economic buyer80 fit
Food-Producing Animals
Strong fit — clear ROI and a fast path to value.
End user67 fit
Aquatic Animals
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Animal Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add API Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel28%
Digital / self-serve22%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Animal Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Veterinary Active Pharmaceutical Ingredients (API) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified25%
Evaluation15%
Closed-won7%
$10.5KCAC
$62KLTV
5.9:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Veterinary Active Pharmaceutical Ingredients (API) Market is a high-growth opportunity — $11.3B by 2033, compounding at 11.4%.
TAM · 2025$4.75Btoday
TAM · 2033$11.3Bforecast
CAGR11.4%2027–2033
Cumulative$68.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$11.3BTotal addressable market
SAM$4.27BServiceable available market
SOM$936MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.4% CAGR
Demand compounds through 2033, outpacing GDP across Animal Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Animal Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$11.3BLarge & growingTAM by 2033 at 11.4% CAGR
$4.27BServiceable nowreachable with today’s model
$936MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$8.80BBear7.4% CAGR
$11.3BBase11.4% CAGR
$14.4BBull15.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & API Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Veterinary Active Pharmaceutical Ingredients (API) Market — a $1.90B market by 2033. Plan: grow share from 7.7% to 16.7%.
Market size · 2033$1.90Btotal addressable
Market CAGR7.8%2027–2033
Target share16.7%from 7.7% today
Revenue ambition$318Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.7% | 16.7% | On track |
| Revenue | $150M | $318M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 30.9% | 43.6% | On track |
| Customer retention | 88.4% | 93.8% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Animal Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build API Type capability
A defensible second engine — invest in API Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Animal Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch API Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $34M capacity & capability investment
- Greenlight bolt-on M&A in API Type
- Authorise North America expansion plan
- Fund R&D program for Animal Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Veterinary Active Pharmaceutical Ingredients (API) Market conversation — a $5.43B market you can size, segment and defend in minutes.
Market size · 2033$5.43Btotal opportunity
Growth3.2%CAGR to 2033
Addressable buyers1,250+accounts in scope
Typical ROI6.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Animal Type
Goal Grow share in Animal Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.4×return on cost, year one
< 4 mopayback period
$89K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
BASF SEEvonik Industries AGZoetis Inc.Elanco Animal Health IncorporatedBoehringer Ingelheim GmbHVirbac SAMerial (now part of Boehringer Ingelheim)Phibro Animal Health Corporation+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Veterinary Active Pharmaceutical Ingredients (API) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Veterinary Active Pharmaceutical Ingredients (API) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Veterinary Abdominal Endoscopy Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportVeterinarian Examining Otoscopes Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportVeterinarian Examining Auriscope Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportVet Ear Examination Device Market
Market size, share, segmentation and regional forecast.
$942M market · 2025 base year
View reportVET Critical Care Analyzer Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportVet Compounding Pharmacies Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportVet Clinic Software Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportVet Chemistry Reagent Disc Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportVet Blood Chemistry Analyzer Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportVest Type Expectoration Machine Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportVest External Defibrillator Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportVessel Sealing Instrument Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.